Elanco Companion Animal Health - maker of Comfortis, the flea treatment for dogs - is hosting an online evening webinar on Tuesday 10th January to highlight what pet owners want from their vets.
The free webinar follows research into the perceptions of clients and veterinary surgeons as to what attributes constitute a 'good vet'1. According to Elanco, the research revealed a distinct mismatch between what vets think and what pet owners think. The webinar will highlight these differences and the steps veterinary professionals can take to address them. Additionally, it will provide veterinary professionals with the opportunity to learn more about Comfortis and ask questions of Elanco's technical consultants.
Presented by Alan Robinson BVSc MRCVS DMS, a business development consultant for independent veterinary practices, the webinar will start at 8.00pm and will account for two hours CPD. Veterinary surgeons and nurses wishing to book a place should visit www.thewebinarvet.com/comfortis.
For further information, please telephone 01256 353131, email elancoCAH.uk@lilly.com or contact your local Elanco key account manager.
'Potential role of veterinary flea products in widespread pesticide contamination of English rivers1, was carried out by Professor Dave Goulson and Rosemary Perkins MRCVS from the University of Sussex and co-authored by Martin (pictured right) and Wayne Civil from the Environment Agency.
For the study, they looked at 3,861 samples taken from 20 rivers around the UK between 2016 and 2018. Fipronil was detected in 98% of the samples and imidacloprid in 66%.
Currently, there are no environmental quality standards for fipronil or the compounds it breaks down into (fipronil sulfone or fipronil sulfide) or for imidacloprid in British surface waters.
The authors therefore used the acute and chronic toxicity limits for fipronil from a report from the Department of Environmental Toxicology at the University of California Davis2, and from Morissey et al (2015)3 for imidacloprid.
They found that the average fipronil concentration across the rivers sampled by the Environment Agency exceeded chronic safety thresholds five-fold. The overall pollution levels in English rivers indicate that fipronil and its toxic breakdown products pose a high risk to aquatic ecosystems.
While, in most rivers, imidacloprid was found to pose a moderate risk, in seven out of the 20 rivers sampled there was a high environmental risk.
The paper, published in Science of the Total Environment, noted that the highest levels of pollution were found immediately downstream of wastewater treatment works, which the authors say supports the hypothesis that significant quantities of pesticide may be passing from treated pets to the environment via household drains.
Professor Dave Goulson said “Fipronil and imidacloprid are both highly toxic to all insects and other aquatic invertebrates. Studies have shown both pesticides to be associated with declines in the abundance of aquatic invertebrate communities. The finding that our rivers are routinely and chronically contaminated with both of these chemicals and mixtures of their toxic breakdown products is deeply troubling.”
Bathing of pets treated with spot-on fipronil flea products has been confirmed as a potentially important route to waterways for fipronil via sewers. The washing of hands, pet bedding or other surfaces that have come into contact with treated pets are potential additional pathways for entry to sewers.
Rosemary said: “We’ve identified a number of steps that can be taken to minimise or avoid environmental harm from pet flea and/or tick treatments. These range from introducing stricter prescription-only regulations, to considering a more judicious and risk-based approach to the control of parasites in pets, for example by moving away from blanket year-round prophylactic use."
Martin said: "The profession urgently needs to adopt ‘responsible use of parasiticides’ similar to the way it is adopting responsible use of antimicrobials. The VMD needs to strengthen the environmental assessment of pet pesticide products in the authorisation process, and they are currently considering this issue. The VMD should also collate and publish annual sales figures for these pesticides as they do for antimicrobials."
He added: "My veterinary hospital has never had a ‘pet health plan’ to provide year round flea products, because we believe that year-round, intensive treatment for almost all dogs and cats does not constitute responsible use of such powerful pesticides."
References
Morrissey, C.A., et al., 2015. Neonicotinoid contamination of global surface waters and associated risk to aquatic invertebrates: a review. Environ. Int. 74, 291–303. https://doi.org/10.1016/j.envint.2014.10.024.
The acquisition of Jurox brings Zoetis a valuable animal health portfolio, including Alfaxan, a leading anaesthetic product for companion animals and high-quality local R&D and manufacturing operations in Australia.
Stephanie Armstrong, Senior Vice President and Cluster Lead UK, BeNeLuX, Nordics & Ireland, said: “We are grateful to the O’Brien family for entrusting the future of this family-owned business to Zoetis.
"Jurox’s portfolio plays to the strengths of our core business and will be a complementary fit with the solutions we deliver to veterinary professionals, livestock producers and pet owners.
"With Zoetis’ global sales and regulatory expertise in more than 45 direct markets, we look forward to expanding the impact and reach of the entire Jurox portfolio here in the UK and Ireland.”
www.jurox.com
James qualified from Glasgow University in 2002 before joining Rosemullion Veterinary Practice, a mixed practice in Falmouth, Cornwall, of which he became a Director in 2008.
In 2014, Rosemullion separated its farm and small animal work, whereupon James became Clinical Director of the new farm practice, Coast2Coast Farm Vets.
In 2015, following the acquisition of Rosemullion and Coast2Coast by CVS, he was appointed to the group's Farm and Equine Clinical Advisory Committees. These Committees comprise clinical staff from across the Farm and Equine Divisions and make decisions on important issues, including purchasing, advice and information for its clinical teams and investments in the latest equipment and facilities.
James said: "I’ll be spending time each week travelling around the UK, Ireland and Holland to visit our farm practices and meet with colleagues within CVS and from the wider farming and veterinary industries.
"During my first six months, I’ll be focusing on developing frameworks and policies that will enable our practices to guide clients through difficult issues, such as antimicrobial and anthelmintic resistance and to help them succeed in the highly competitive marketplace for both prescription and non-prescription medicines.
"I will also be creating a bespoke farm New Graduate Programme for young vets which all our farm practices will be able to access.
"I see an exciting opportunity for CVS Farm to become a major force in the sector and am looking forward to working with my new colleagues to bring this about."
Clare graduated from the University of Glasgow in 1991 and, following an internship at the University of Pennsylvania and general practice in Cambridgeshire, she completed a BSAVA/Petsavers Residency and was Staff Clinician in Neurology at the Royal Veterinary College.
Aged 26, she became the youngest ever Diplomate of the European College of Veterinary Neurology and three year later became a RCVS Specialist.
For 16 years, she operated a neurology and neurosurgery referral service at the Stone Lion Veterinary Hospital in Wimbledon and was awarded a PhD from Utrecht University in 2007.
Clare joined Fitzpatrick Referrals and the University of Surrey in 2013, was made a Fellow of the Royal College of Veterinary Surgeons in 2016 and awarded a Professorship of Veterinary Neurology in 2018.
Clare was made a Fellow of the Royal College of Veterinary Surgeons in 2016 in recognition of her meritorious contribution to the profession, including 25 years’ research into ‘Chiari-like malformation and syringomyelia’ in dogs.
Clare said: “I will be building and strengthening the neurology service at Wear to make it not just the leading centre in the North East, but in Europe.
“I love collaborating with others to find answers to the clinical problems we face and so, as well as potential partnership with my colleagues in the other disciplines at Wear, I hope to initiate or contribute to other multi-centre studies through the Linnaeus group.
“I am passionate about teaching and learning through collaboration, and I hope to bring multi-disciplinary rounds to the practice including neuro-radiology-neuropathology and neurology- behaviour.”
The two-day event, now in its fifth year, aims to combine world-class CPD for the whole practice team with an outdoor ‘festival’ atmosphere.
The organisers say that the wellbeing of veterinary professionals has always been a strong focus of VET Festival, but the inclusion of Lara Heimann in the Wellness and Practice Development lecture, takes it to a new level. Laura has developed her own vinyasa yoga style and regularly leads international retreats and workshops.
Speakers in the clinical programme will include:
Dr Antonio Pozzi, Head of the Clinic for Small Animal Surgery at the University of Zurich, Switzerland
Dr Susan Little, co-owner of two feline specialty practices in Ottawa, Canada, and past president of the American Association of Feline Practitioners
Dr Ronaldo da Costa, Professor in Neurology and Neurosurgery at Ohio State University, USA.
Veterinary cardiologist Professor John E Rush. A Diplomate of both the American Colleges of Veterinary Internal Medicine and Emergency and Critical Care, Dr Rush has been a professor for 25 years at the Cummings Veterinary Medicine Centre at Tufts University in Massachusetts
Behaviourist Dr Sarah Heath. A founding Diplomate of the European College of Animal Welfare and Behavioural Medicine
Soft-tissue surgeon Professor Christopher Adin. Professor Adin is Chair of the University of Florida’s Department of Small Animal Clinical Sciences and Associate Professor of Soft Tissue.
Veterinary nurses are welcome to attend any of the lectures, in addition to those in the dedicated nursing stream. An exhibition of the latest products and services for all veterinary professionals takes place in a dedicated arena.
Nicole Cooper, event director, said: "VET Festival is unique in bringing together cutting-edge, inspirational learning, fun and the great outdoors. CPD from our world-leading speakers is delivered in a high quality and contemporary setting but, once work is done, we encourage delegates to relax and enjoy free admission for them, their friends and family to the VETFest Live Party Night."
She added: "With the wellness and wellbeing of members of our profession increasingly in the spotlight, we’re delighted to welcome Lara Heimann for 2019 and hope that she will help our delegates to develop practical solutions to living healthier and more balanced lives."
Supported by MWI Animal Health, VET Festival also offers a 'Family Hub', a place where children can play whilst their parents listen to lectures.
Alan White Group Commercial Director at MWI Animal Health, said: "Balancing work and family life can often be a juggling act, particularly in the veterinary profession where time is in short supply. This can sometimes compromise the work-life balance of vets, nurses and other team members. At VET Festival, the 'Family Hub' means that there is no compromise and that both our attendees and their families can get the best out of their time with us."
You can buy tickets here: https://www.vetfestival.co.uk/delegate-info/ticket-information
The Animal Health Trust and the Kennel Club have announced that a new, non-invasive DNA test for the genetic mutation causing macular corneal dystrophy (MCD) in Labradors will be available from the Animal Health Trust DNA Testing Service from Monday 26 January 2015.
Macular corneal dystrophy (MCD) is a hereditary eye disease which, although painless, causes severe visual impairment in affected dogs.
The mutation for MCD is recessive; meaning only dogs that inherit two copies of the mutation will be affected. Dogs identified by the test as Clear have no copies of the mutation whereas Carriers have one copy of the mutation. Clears and Carriers cannot develop MCD, although Carriers will pass the mutation on to about half of their puppies if they reproduce. Dogs identified as Genetically Affected have two copies of the mutation and will develop MCD around middle-age. The DNA test can be used to screen dogs at any age and provides a means of eliminating the causal mutation from the Labrador Retriever gene pool.
Dogs affected with MCD will develop cloudy eyes, due to an abnormal accumulation of carbohydrates (known as glycosaminoglycans) in their corneas. The only treatment for the disease in people is to surgically perform a corneal transplant; however this has not yet been performed successfully in the dog for the treatment of MCD.
Dr Cathryn Mellersh, Head of Canine Genetics at the Animal Health Trust, said: "We're really pleased to be able to provide this new test in 2015. Screening Labradors for the mutation responsible for this condition will help to identify those dogs at risk of developing MCD, and/or passing it on to their puppies. Dogs don't typically develop MCD until middle age - so without a DNA test there is a chance that affected dogs are unknowingly bred from. Now, affected and carriers dogs can easily be identified through one simple test giving breeders peace of mind.
"By developing this test and encouraging screening within the Labrador population we hope that this horrible disease can now be eliminated from the breed. This is the aim behind all of our work in canine genetics and we're thrilled to have been able to make such good progress in developing this test after MCD was first reported in Labradors by one of own veterinary ophthalmologists in 2013. Since then we've worked closely with the ophthalmology team here at the Animal Health Trust and Labrador owners and breeders from various European countries and have managed to identify the mutation and launch this test within two years, which is great news for Labrador owners."
Caroline Kisko, Kennel Club Secretary, said: "The Labrador is the most popular breed in the UK, so there is certainly a high demand for puppies, and it is crucial that those being bred are as healthy as possible.
"This test will further assist breeders of Labradors in breeding healthy, happy examples of the breed and we are delighted to be able to offer another tool to improve and maintain the breed's health.
"The work carried out at the Kennel Club Genetics Centre at the Animal Health Trust really does make a massive difference to the lives of dogs and we are thrilled that Labrador breeders will now be able to make use of another health test to protect the health of the breed they love."
For more information, visit www.ahtdnatesting.co.uk. The test costs £48 inc VAT, with a 10% discount when at least 20 samples are submitted within a month. Interested parties should contact dnatesting@aht.org.uk with a start date to request a discount code.
The British Veterinary Association has responded to 'alarmist' headlines linking contact with cats to schizophrenia due to the risks posed by the parasite Toxoplasma gondii.
The report in today's Independent contains some important messages regarding the need for good personal hygiene and the need for pregnant women and immuno-compromised groups to be aware of the risks. However, the BVA says it is concerned that the headlines could cause significant alarm to cat owners.
Most people who become infected are asymptomatic but 10-20% can show transient symptoms which are flu-like. There is a more serious risk to pregnant women and those who are immuno-compromised, but as with all infections common sense and good personal hygiene reduces the risk significantly and the BVA says there is no reason that families with, or those intending to have, children shouldn't have pet cats.
As outlined in the article sources of infection include eating undercooked meat and vegetables that have not been washed properly and contact with cats. It is not known which the greater source of infection is but according to the BVA, anecdotal evidence suggests that meat is likely to be more important than contact with cats. The BVA says it echoes advice that meat should be prepared and cooked properly, and offers the following hygiene advice for cat owners:
BVA Past President and veterinary surgeon Harvey Locke said: "While the facts are true, the headlines in this story have been quite alarmist and we are very keen to reassure cat owners that the risks can be managed with good basic hygiene and common sense.
"The biggest threat is to pregnant women and those who are immuno-compromised, which we have known for some time. It is useful to reiterate that they should take extra care but there is no need for people to get rid of their pet cats or choose not to have cats as pets."
The Sutton Bonington Campus, home of the University of Nottingham's School of Veterinary Medicine and Science, has raised £610 for Sport Relief with its annual Science Cake Competition.
There were thirty entries to the competition, in categories which included Animals & Agriculture, Food & Nutrition, Infection, 'Nerdy' Science, Plants, Crops & Environment, and Veterinary Medicine.
A special category this year was 'Cakes for Animals', which Emily Blight, an undergraduate vet student, organised for a panel of dogs to judge on tastiness.
The winner of the public vote was 'What came first, the chicken or the cake?' (pictured right), whilst the overall winner was Alex Burgess with ‘Dave’s Allotment’.
One of the judges, Dr Mike Jones said: "Choosing the winner was extremely hard. Every cake had its own specific merits be it the execution of the design, through to the novelty of ingredients and ideas or how they fitted into the categories." He added that he "was almost put off jelly beans for life - they will be forever associated with sheep back sides."
The cakes are all on display here.
Zenifel contains synthetic feline facial pheromones which imitate the facial F3 pheromone which has been found to be significantly important when it comes to cats creating areas they feel safe and relaxed in1.
According to the company, Zenifel contains a 48ml vial of the same synthetic F3 feline facial pheromone as the market leader, but, thanks to its own diffusion system and a higher concentration of F3, lasts up to 6 weeks; i.e. 50% longer. This, says Virbac, means that Zenifel is both more economical and more environmentally friendly.
Alongside the launch of the new product, Virbac is offering a practice support pack which includes things you need to create a calm area for feline visitors and promote the benefits of pheromones to pet owners. The company is also running a promotion in which practices could be eligible for a year’s free supply of Zenifel.
For more information, contact your local Virbac Territory Manager.
Reference
A man who worked as a veterinary surgeon in Wiltshire, despite being neither qualified nor registered with RCVS, has received a 20-month sentence at Swindon Crown Court.
Peter Keniry (also known as Patrick Keniry), from Great Yarmouth, had been practising under the name of a properly qualified and legitimately registered veterinary surgeon, and was arrested on 23 August. At his initial hearing in Swindon Magistrates' Court, Mr Keniry pleaded guilty to charges of fraud by misrepresentation and unlawfully practising as a veterinary surgeon, and was released on bail.
At the Crown Court on Friday, Mr Keniry also pleaded guilty to additional charges before being sentenced. It is understood he will serve a number of months in prison, before being released on licence for the remaining period.
The RCVS assisted Wiltshire police in their apprehension of Keniry in August, having been alerted the previous day to his fraudulent activities. Mr Keniry is no stranger to the College or the police, having already been dealt with in 1998, 2001 and 2005 for similar offences. On each occasion, Mr Keniry has impersonated a member of the College whose name is legitimately on the Register, which makes it difficult even for practices that do check the credentials of prospective employees to pick up a problem.
Commenting on the recent sentencing, Gordon Hockey, RCVS Head of Professional Conduct said: "We are satisfied that the Court has clearly recognised the risk posed to both animal welfare and public safety by bogus veterinary surgeons. Anyone working as a veterinary surgeon when not qualified to do so, risks a custodial sentence.
"Mr Keniry's continued pattern of re-offending shows him to be a very convincing fraudster. By publicising his photograph, we hope to help any potential employer or locum agency reduce the chances of this happening again," he added.
DogStem has been shown to be effective, reducing pain and lameness and improving mobility and quality of life for three months to over twelve months following a single injection1,2.
In a prospective, randomised, double-blinded, placebo-controlled trial of DogStem, results showed that2:
TVM highlights how DogStem simplifies the process and reduces the cost of using stem cell therapy in practice because unlike previous therapies, it does not require require a surgical harvesting procedure to be carried out under general anaesthetic.
Helen Harrison, DogStem Technical Vet and Product Manager said: "Osteoarthritis is one of the most common diseases seen in veterinary practices and is challenging to manage.
"Conventional medical treatments typically address the symptoms rather than the underlying pathological processes.
"At the same time, local treatment options that slow progression of osteoarthritis have been limited and surgical interventions aren’t always possible or may be unrewarding.
"We’re delighted to be able to offer vets DogStem®, a stem cell product with a strong evidence base across numerous mobility and quality of life parameters.’
DogStem can be ordered from NVS, or direct from: www.dogstem.co.uk
The dog, called Pepe, needed urgent treatment to repair the cornea before it ruptured, so the team at Davies decided to use a new xenograft derived from a pig cornea, rather than waiting to see if an allograft became available.
The xenograft, which was developed in China, is aseptically prepared, sterilised and freeze-dried so it can be stored for months or years if necessary before use.
According to Davies, the graft had been used in China and the USA, where the early results had been promising. Now, following Pepe's successful treatment, Davies is now using the procedure in more cases over here in the UK.
The full case study, with photos, is here: https://www.vetsurgeon.org/veterinary-clinical/small-animal/sa-ophthalmology/m/photo-video-media/138076.aspx
For more information, visit: https://vetspecialists.co.uk/services/ophthalmology/
The Care About Cushing’s website is designed to give horse owners the information they need to spot the signs of Cushing's, thereby prompting diagnosis by their veterinary surgeon.
The online resource includes monitoring tools, personalised alerts, owner guides and webinars. It also offers downloadable self-assessment checklists on Cushing’s disease and laminitis to take owners through the signs to look out for.
Owners whose horses have been diagnosed with Cushing’s are encouraged to sign up as a Care About Cushing’s member to keep up-to-date with the latest information about the disease and create a personal profile for their horse in order to monitor progress. One of the membership benefits is an 'ask the expert' section where members can ask questions about Cushing’s disease and laminitis.
The Care About Cushing’s resource supports Boehringer’s ‘Talk About Laminitis’ initiative to raise awareness of the signs of laminitis and its link with Cushing’s disease.
Talk About Laminitis now runs throughout the year and as part of the campaign the laboratory fees for the blood test which detects Cushing’s (the basal ACTH test) are free.
Liz Barrett, equine business head at Boehringer, said: "Our Talk About Laminitis disease awareness initiative has been hugely successful in highlighting the link between laminitis and Cushing’s disease and helping to diagnose Cushing’s. So much so that Cushing’s is now in the top five equine diseases recorded in the UK1."
For further information on Talk About Laminitis or Care About Cushing’s, visit www.talkaboutlaminitis.co.uk, www.careaboutcushings.co.uk or contact your local Boehringer territory manager.
MSD's push is being driven by the rising number of cases of Leishmaniasis cases in the UK, including the first report earlier this year of dog-to-dog transmission of the disease.
Caroline Darouj, Product Manager at MSD Animal Health said: "Whilst accurate statistics on the number of cases seen in UK practices are not available, the VMD has reported an annual increase in the number of leishmaniasis treatments imported since records started in 2006.
"Based on applications for Special Import Certificates for Milteforan and Glucantime, there were 27 times as many cases treated in 2018 (439) compared to 2006 (16)*.
"Leishmaniasis is proving to be a significant threat to travelling dogs, a situation that has been widely reported in the vet press, so LetiFend will offer veterinary practices and dog owners throughout the UK reassurance. A single dose primary course given four weeks before travel makes it ideal for non-regular travelers."
Letifend is indicated to reduce the risk of developing active infection and/or clinical disease after exposure to L. infantum from 28 days post vaccination1,2. It offers protection for 365 days after a single annual dose. The company says it has excellent tolerability shown in a wide range of breeds and ages, and in field trials in areas at high risk of infection had an efficacy rate of 72%4.
LetiFend is a non-adjuvanted vaccine which MSD says ensures a targeted immune response with a high level of safety.
MSD says a dog vaccinated with LetiFend is at 9.8 times less risk of presenting clinical signs, at 3.5 times less risk of presenting parasites, and thus at 5 times less risk of developing clinical leishmaniasis1. It can be applied from six months of age via subcutaneous administration.
For further information contact your MSD Animal Health account manager.
*Information from VMD following a Freedom of Information Act request.
The programme offers a structured and heavily supported first year in practice, including hands-on surgical training and seminars from Advanced Veterinary Practitioners, at the Pets'n'Vets' Roundhouse Veterinary Hospital in Glasgow.
Totally Grad! also includes a mentor plan and additional monthly benchmarking and seminars and support.
Oliver Jackson, partner at Pets'n'Vets said: "We are well aware that many larger veterinary entities run new graduate programmes and we are proud to say that Totally Grad! offers great advantages that come with our independent structure.
"Independent practice can offer a rewarding working environment for new graduates – particularly progressive practices such as ours. We can offer new graduates not only the close-knit, friendly, helpful, stable, first-opinion experience, but also provide opportunities for career growth and development.
"We have the facility for graduates to explore their particular areas of interest. Indeed, in our practice it is possible for a new graduate to change our way of working – the decision-makers are available and listening. We now have many vets working with us who have come through the practice from our graduate system and who have gone on to help shape our practice.
"The success of our Laparoscopic and Cardiology clinics can be attributed to those vets, as can various other client service initiatives and ways of working. New blood brings new ideas and we welcome that."
Totally Grad! will also be open to fellow independent practices.
Oliver added: "By opening up our Totally Grad! programme, we are offering a simple, accessible facility to those fellow independent practices able and willing to provide a mentor and allow their graduate vets to be out of their practice for one or two days per month over a 12 month period. It fits perfectly with our Roundhouse Referrals offering which offers advice, CPD and support to local practices."
Any independent practices interested in participating in the programme can contact oliver.jackson@petsnvets.org while final year students interested in learning more about the programme can visit the website at www.totallygrad.co.uk and/or email Karen W at hello@totallygrad.co.uk
The company says that as soon as it discovered the unauthorised external access to its systems, it took them offline and started working to contain the threat.
Specialist third party consultants have been engaged to investigate the nature and extent of the incident and CVS has also informed the relevant authorities, including the Information Commissioner’s Office, because of the risk of malicious access to personal information.
The company says the majority of IT services for its practices and business functions have now been restored, but due to the increased levels of security and monitoring, some systems are not working as efficiently as before.
CVS also says that as a result of the incident, it is bringing forward plans to migrate its practice management system and related IT infrastructure to the cloud.
Analysis of the incident is ongoing and CVS says it will provide a further update in due course.
For the studies, the owners of 68 dogs treated with Librela and 44 cats treated with Solensia answered 22 questions in the case of dogs and 20 questions in the case of cats on VetMetrica, a digital HRQL instrument.
With a scale of 0-6, cats were rated on vitality, comfort and emotional wellbeing, and dogs on energetic/enthusiastic, happy/content, active/comfortable and calm/relaxed, over a period of 70 days.
The studies concluded that both Librela and Solensia produced a significant improvement in HRQL within 14 days of initial treatment, which was the first time the QOL impact was measured.
The improvement was maintained for the duration of the study.
Jacky Reid, BVMS PhD DVA, CEO of NewMetrica, now part of Zoetis, said: “Assessing and understanding how OA-related pain impacts emotional and physical well-being in particular circumstances, broadens the perspective in relation to pain management.
“HRQL measurements are not generally implemented in veterinary science at this time, so it’s exciting to see how it’s proving effective at adding value to existing functional measures.
"Particularly, helping us understand how pain management impacts the physical and emotional wellbeing of animals and will ultimately boost pet owner confidence.”
Oya Canbas, Zoetis UK General Manager, explained: “With an ever-growing bond between humans and animals, and pets leading longer lives, pet owners are more motivated than ever to support their pet’s wellbeing.
"However, not all are aware of the negative impacts of chronic disease, with signs of OA pain often mistaken as ‘normal’ signs of aging.
"This is why we need to increase awareness, to tackle under-diagnosis of OA pain.
"Common medications used to treat cases of OA pain that are diagnosed are often Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
"While effective, these can have limitations, such as for middle aged to senior pets which have other diseases, requiring multiple medications.
"Some will not tolerate NSAIDs, and not all pets respond to NSAID therapy.
"So, expanding prescription choices is a privilege.”
Two analyses of the pet insurance market have been published this week, which together suggest that veterinary practices may be starting to price themselves out of the market.
Both reports are titled Pet Insurance 2014. In the first, published by Key Note Ltd, authors highlight a 35.4% increase in gross claims incurred on cat and dog insurance policies between 2009 and 2013, which is more than 5 times the increase in the volume of claims over the same period. It is the degree to which the value of claims has outstripped the volume which the report describes as 'undeniably the greatest factor affecting the UK market for pet insurance.
At the same time, there has been a relatively modest growth in the percentage of adults that own a cat or dog (around 1.5 percentage points). Consequently, premiums increased by 38.9% between 2009 and 2013 as insurers responded to the growing cost of claims.
Meanwhile, the other Pet Insurance 2014 report, this time from YouGov, has shown that the main factors limiting the uptake of pet insurance are poor value for money and the high cost of premiums. In 2012, 31% of owners without insurance said it was not good value for money, and that was the main reason for not taking out cover. By 2014, that figure had risen to 39% of the uninsured and 26% said they just cannot afford premiums.
According to the YouGov report, the words that uninsured pet owners most associate with pet insurance are 'expensive' (68%) and 'waste of money' (30%). Even 57% of those with insurance deem it expensive.
YouGov also highlighted that the number of uninsured pet owners who say they can afford to pay for veterinary treatment out of their own pockets (without setting money aside each month) has increased 4 percentage points from 15% in 2012 to 19% in 2014. YouGov hypothesises that this may be down to the improving economic situation in the UK, but it could equally be explained as just the way hard-pushed people self-justify their decision to discontinue insurance.
James McCoy, Research Director, YouGov Reports said: "Although social grade is important to being able to afford to take out pet insurance, our research suggests that those at different ends of the financial spectrum share the opinion that cover is not necessarily always a sound financial option.
"More affluent pet owners find insurance poor value because they can afford to pay for treatment up front; for less affluent pet owners, while pet insurance is perceived as offering good value for money, the cost of premiums is prohibitive, leading some to save money instead."
Teddy had initially been examined at another specialist centre where life-long medical management was recommended due to the complexity of his vascular abnormality.
His primary care veterinary surgeon, Dr Rachel Lang, then referred the case to Gerard.
The first step was a contrast CT scan of Teddy's liver to highlight the vascular abnormalities and take accurate measurements.
Teddy then underwent a transjugular coil embolisation of his shunts using fluoroscopic guidance.
This involved placing a stent in his caudal vena cava that spanned both abnormal communications, and then deploying multiple platinum coils into the shunts to occlude the vascular flow while ensuring portal hypertension did not develop. The entire procedure was completed in less than 60 minutes and was performed via a 2cm skin incision over his jugular vein.
Teddy made an excellent recovery from the procedure and is currently free of clinical signs and receiving no medication at home.
Rachel said: "I was really struggling to find a referral centre willing to take on Teddy's case as it was so unusual and had spent weeks contacting every local referral centre I had referred to in the past. I contacted Fitzpatrick's about his case and within an hour Gerard McLauchlan had rung back and actually sounded keen to see Teddy which was a delight after weeks of frustration. The referral process was very easy from my side and I've been kept well informed throughout. I wouldn't hesitate to refer a case again and only wish we were closer!”
Gerard said: “Teddy is a wonderful patient with an amazing family. We were delighted to be able to offer a solution to his problem that had been previously thought not possible. Teddy should now be able to enjoy an excellent quality of life without the need for long term medications or diet. Interventional Radiology provided new and minimally invasive options for many conditions including vascular abnormalities, urinary tract problems and various cancers.”
You can view the CTs in the VetSurgeon Clinical Reference Library here.
Dechra Veterinary Products has launched a 5 ml bottle of Comfortan (methadone), its titratable analgesia for cats and dogs.
The new sized bottle of Comfortan, designed for use with animals in, or about to experience, moderate to severe pain, is now available from veterinary wholesalers.
Dechra Brand Manager Craig Sankey said: “The new 5ml bottle is a great size for practices which would like to introduce Comfortan into their practice protocols, allowing them to do so in a cost-effective way.
“The availability of a smaller bottle will also be a benefit to practices which due to different surgical needs, currently only use Comfortan in a small number of cases. They will then be able to simply and easily trade up to the 10 ml bottle once they start to use Comfortan on more cases.”
The 5 ml has also been introduced in response to demand from branch practices which had been transferring 10ml bottles between sites and for cat-focused practices which use smaller volumes of the product.
This list was originally prepared BVDA President, Alex Smithson after being asked by lots of colleagues which dentistry CPD he knows of or recommends.
To his list, we've also added events hosted by Improve International and Bob Partridge.
In addition to the following courses, Orosurgeon Ltd provides in-house, group and individual training throughout the year. Courses can cover all dentistry and oral surgery topics, basic to advanced, including restorative & endodontic dentistry.
Contact admin@orosurgeon.co.uk for details.
The awards celebrate the achievements of remarkable people from the farming, veterinary and charity industries, who go beyond the call of duty to better the lives of animals around the world. Nominations were submitted by friends, family, clients and colleagues.
Spanning six categories, the shortlist for the 2018 Ceva Animal Welfare Awards is as follows:
Chris Laurence Vet of the Year Award supported by Your Dog and Your Cat magazines
Vet Nurse of the Year Award supported by Agria Pet Insurance
Charity Team of the Year supported by PDSA
Charitable Contribution of the Year supported by Blue Cross
Farm Animal Welfare Award supported by R.A.B.I. and NADIS
International Cat Care Welfare Award
International Cat Care will be choosing the winner of this award from its extensive membership base. The winner will be announced at the awards’ ceremony.
In addition to the scheduled categories, the judges have granted one additional award in special recognition of an individual’s lifetime commitment to animal welfare.
The shortlist for each award was decided following a day of deliberations by a panel of judges chaired by retired veterinary surgeon, Chris Laurence MBE FRCVS. Chris is chairman of the Animal Welfare Foundation, the Canine and Feline Sector Group of the Animal Health and Welfare Board and BVBA (British Veterinary Behaviour Association) and before retiring he was chief veterinary officer at the RSPCA and veterinary director of Dogs Trust. He is also involved in a number of charities and is a trustee of the Pet Blood Bank and the Bella Moss Foundation.
Chris said: "Judging the ever-increasing number of nominations takes a lot of work, just to read them all let alone deciding who should go forward as a finalist. The standard of nomination improves every year and each is an inspiration to the judges because of the selfless effort put in by each nominee to improve animal welfare, often in the most difficult circumstances."
Cuneyt Seckin, managing director of Ceva Animal Health, added: "Year-on-year we are amazed and humbled by the individuals and organisations who dedicate their lives to enhance and improve animal welfare both in the UK and abroad. We are delighted to be able to honour these people, while highlighting their important work to a wider audience."
The winners will be announced and presented with their awards during a ceremony held in Birmingham ahead of BSAVA Congress on 4th April 2018.
To find out more about the awards, visit: www.cevawelfareawards.com.
Elanco Companion Animal Health has launched Recuvyra 50mg/ml transdermal solution for dogs, the first transdermal fentanyl solution to be licensed for the control of postoperative pain associated with major orthopaedic and soft tissue surgery.
Recuvyra is a schedule two controlled drug which contains fentanyl, a pure μ-agonist synthetic opioid with a potency 100 times that of morphine1. Applied to the area between the shoulder blades by a needleless two-pronged adapter two to four hours prior to surgery, Elanco says Recuvyra provides at least four days of opioid analgesia, which is mainly due to the activation of the μ-opioid receptors inhibiting the perception of pain and the transmission of pain signals in the spinal cord and dorsal horn2.
Elanco says Recuvyra's unique formulation provides long-lasting analgesia by establishing a depot of fentanyl within the stratum corneum. The fentanyl in this depot undergoes passive diffusion down a concentration gradient, and is steadily released into the general circulation over a number of days.
Ed Whittle MA VetMB MRCVS, technical consultant at Elanco said: "Fentanyl is widely used in human health and its powerful analgesic properties are well known amongst veterinary surgeons1, 3, 4. Recuvyra is a ground-breaking veterinary product that will provide long-acting post-operative pain control in dogs while reducing the need for repeated, invasive administration of analgesics in the practice and improved client compliance and the potential for mutimodal analgesia once a dog returns home."
To ensure proper use of Recuvyra, Elanco has produced a mandatory online training programme for veterinary surgeons to complete before ordering the product. The brief online training module, which can be viewed at www.recuvyratraining.eu, features information on the presentation, correct preparation and administration of the product, and the safe handling of patients that have been treated with Recuvyra. Once veterinary surgeons are trained, it is their responsibility to train their staff on the in-practice use of Recuvyra and Elanco has produced a training presentation to help educate veterinary professionals about the product.
To support the launch of Recuvyra, Elanco has produced a dosing calculator, cage cards and client information sheet. For further information on Recuvyra, please contact your Elanco Companion Animal Health key account manager or email elancocah.uk@elanco.com.
Rodney (pictured right) has spent the last 26 years practising in the USA, latterly at the California-based Advanced Veterinary Specialists & Animal Specialty Group.
After growing up in Zimbabwe and graduating from the University of Pretoria in South Africa in 1985, he moved to London, where he became an MRCVS, and thence to the USA.
He undertook a small animal internship at the Animal Medical Centre in Manhattan, before moving to the Ohio State University for his residency in medical oncology in 1989. He achieved Board Certification in medical oncology in 1994 and in radiation oncology in 2000.
Rodney specialises in the application of multi-modality therapy protocols for the treatment of cancer in animals, and has conducted research on the phenomenon of multi-drug resistance, mast cell tumour and oral melanoma.
He said: "Thirty-something years on, I have come back to the UK as a specialist, where I started as a GP. Living in the UK also brings me much closer to my family, which is very important to me.
"Over the years, veterinary practice in the USA has changed significantly, where it has become more corporate and less personal. I enjoy being part of a new group where typically it is much closer, friendlier and more like a family."
Rodney now plans to oversee the development of a comprehensive oncology department to include chemotherapy, surgery, radiation therapy, immune-therapy and molecular targeted therapy.
He said his work at Paragon will focus on educating referring vets and clients about what is possible in the oncology field.
He said: "My job will be about increasing the level of knowledge, both of owners and general practitioners, of how we treat cancer in animals.
"It can be a scary disease and the first door an owner needs to step through, is understanding that treating a pet is very different to treating a human.
"The intention in humans is usually to cure but with pets, it is more about providing a good quality of life for as long as possible.
"There can be a fear of cancer therapy but if you stick to the protocols, it is no different to treating any other chronic incurable diseases. We use the safest methods with an abundance of caution and try to make sure that the treatment is not worse than the disease.
"It’s about internal training too, from reception right up to nurses and interns, looking at what we do and how we do it, to optimize the quality of life of the pet and their owners.
"I would like to see an oncology department that considers the emotional, financial, time and patient concerns of the owners, so they feel their commitment to cancer treatment for their pet is not a commitment to putting their pet or themselves through a difficult time."